To assist members in navigating the No Surprises Act final rule, CHA will host a complimentary webinar from 11 a.m. to noon (PT) on Sept. 30.
Join CHA’s Chad Mulvany and Amanda Hayes-Kibreab, partner at King & Spalding, as they provide insight and guidance for members navigating the No Surprises Act final rule.
As previously announced in CHA News, the California Department of Health Care Services (DHCS) and its Medi-Cal Rx contractor Magellan will reinstate pharmacy claim edits and Reject Code 88 for diagnosis and drug utilization review requirements on July 22.
Livanta, Medicare’s national claims review contractor, has launched the Livanta Claims Review Advisor — a monthly online educational resource for medical coders, billing, financial and revenue cycle personnel, clinical documentation improvement specialists, utilization review coordinators, case managers, compliance officers, physicians, and other practitioners.
On Oct. 20, the Food and Drug Administration amended the emergency use authorization for COVID-19 vaccines to allow booster doses for the Moderna and Johnson & Johnson vaccines. The Centers for Medicare & Medicaid Services has released new billing coding for the Johnson & Johnson and Moderna COVID-19 vaccine booster shots. Current billing codes, payment allowances, and effective dates are available online.
The Centers for Medicare & Medicaid Services has announced will pay the full cost of the Pfizer-BioNTech COVID-19 booster shots to providers without cost-sharing for Medicare, Medicaid, and the Children’s Health Insurance Program beneficiaries.
On Sept. 10, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule detailing the enforcement provisions related to the No Surprises Act (NSA). The proposed rule:
The Food and Drug Administration (FDA) today announced its full approval for the Pfizer-BioNTech COVID-19 vaccine — under the name Comirnaty — for individuals 16 and older, making it the first COVID-19 vaccine to go beyond emergency use authorization (EUA) in the U.S.
On Aug. 12, the Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for both the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines to allow for the use of an additional dose in certain immunocompromised individuals ages 12 and older. Following that announcement, the Centers for Disease Control and Prevention issued a recommendation that […]
The Centers for Disease Control and Prevention (CDC) announced plans to begin offering COVID-19 booster shots to all individuals beginning the week of Sept. 20 and starting eight months after an individual’s second dose, pending authorization from the Food and Drug Administration (FDA) and a review by the CDC’s vaccine advisory committee.